The 2025 ASSET-IT trial investigated whether early intravenous infusion of tirofiban, an antiplatelet agent, following intravenous thrombolysis could improve outcomes in patients with acute noncardioembolic ischemic stroke who are not eligible for thrombectomy. This phase 3, double-blind, randomized, placebo-controlled study … Read More
Blog
E3 Trial: Do e-Cigarettes Help Smokers Quit?
Published in JACC Advances, June 2025 The E3 Trial evaluated whether short-term use of nicotine or non-nicotine e-cigarettes, combined with counseling, improves smoking abstinence at 1 year. This multicenter, randomized controlled trial adds critical insight into smoking cessation strategies. 🧑⚕️ … Read More
Advance-HTN Trial: Lorundrostat in Uncontrolled Hypertension
Hypertension remains a major global health issue, particularly for patients whose blood pressure remains uncontrolled despite multiple medications. The Advance-HTN trial, presented at ACC.25 in Chicago in 2025, provides compelling evidence for the use of lorundrostat, a novel aldosterone synthase … Read More
DapaTAVI Trial: Dapagliflozin in TAVR
The year 2025 brought several influential cardiovascular studies to light, and among the most promising was the DapaTAVI trial. This randomized, open-label trial explored the impact of dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, in a population often seen as high-risk … Read More
WARRIOR Trial: Women’s Ischemia Trial, Treating Non-Obstructive Coronary Artery Disease
In the ever-evolving landscape of cardiovascular research, the WARRIOR trial—short for Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD—has emerged as a pivotal investigation into how best to treat women with ischemia and no obstructive coronary artery disease (INOCA). … Read More
API-CAT Trial: Evaluating Low-Dose Apixaban for Cancer-Associated Thrombosis
API-CAT Trial: Evaluating Low-Dose Apixaban for Cancer-Associated Thrombosis Introduction The API-CAT trial is a groundbreaking study designed to evaluate whether a reduced dose of apixaban (2.5 mg twice daily) is as effective as the standard full-dose regimen (5 mg twice … Read More
BASIL-3 Trial: Evaluating Endovascular Strategies in Severe Leg Ischaemia
Staying up to date with landmark clinical trials is essential for evidence-based patient care, especially in fields like vascular surgery and interventional cardiology. The recently published BASIL-3 trial sheds light on the best endovascular approach for patients with chronic limb-threatening … Read More
Aortic Stenosis Severity Algorithm
Aortic Stenosis Severity Algorithm (ACC/AHA 2020 Guidelines) Step 1: Assess Aortic Valve Morphology and Function Step 2: Quantify AS Severity (Echocardiographic Parameters) Severity AVA (cm²) Mean Gradient (mmHg) Peak Velocity (m/s) Dimensionless Index (DI) Mild >1.5 <20 <3.0 >0.5 Moderate … Read More
IVUS-ACS Trial: Intravascular Ultrasound vs. Angiography for PCI in Acute Coronary Syndromes
IVUS-ACS Trial Summary Introduction In the management of acute coronary syndrome (ACS), optimal guidance for percutaneous coronary intervention (PCI) remains a critical factor in improving patient outcomes. The IVUS-ACS trial, a large, multicenter, randomized study, investigates whether intravascular ultrasound (IVUS)-guided … Read More
ADAPT-Sepsis Trial: PCT vs. CRP-Guided Antibiotic Duration
Understanding the ADAPT-Sepsis Trial: PCT vs. CRP-Guided Antibiotic Duration Sepsis remains a critical challenge in intensive care units (ICUs), often requiring prolonged antibiotic use. The ADAPT-Sepsis trial, published in JAMA (2024), aimed to determine whether procalcitonin (PCT)-guided or C-reactive protein … Read More